*Plasmodium falciparum* is the causative agent of the most dangerous form of malaria, a disease that affects approximately 200 million people every year in tropical areas of the world ([@B52]). Immunity against malaria is only acquired after successive malaria episodes and is strongly dependent on the generation of specific B-cells, antibodies and a functional T-cell memory response ([@B29], [@B15], [@B50], [@B36]). Multiple targets of antibodies have been identified on the merozoite surface or localised to organelles within it and many of them are being considered as potential vaccine components ([@B46]). The infected red blood cells (IRBCs) and the variant parasite proteins directed to its surface are also important targets for antibodies and it has been shown that cumulative exposure increases the breadth of the recognition of antigenic variants that are displayed ([@B20]). A major portion of antibodies seems to be directed against variants of the *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) ([@B26], [@B12], [@B13]), which are important virulence factors because they mediate the cytoadhesion of IRBCs to a variety of receptors found in endothelial tissues \[reviewed in [@B35]\], thus allowing the IRBCs to avoid spleen clearance. PfEMP1 variants are encoded by the *var* gene family and consist of 50-60 alleles per haploid genome ([@B8], [@B41]); they are expressed in such a way so that only one or a few *var* gene *loci*([@B21]) are active per infected RBC, leading to the exposure of only one (or a few) species of PfEMP1. In a timely fashion, the *var* gene *locus* activation is altered by chromatin modification so that PfEMP1 expression switches \[reviewed by [@B18]\]. This leads to a constant immune evasion of the circulating IRBCs, which is termed antigenic variation. Due to the accelerated genetic recombination of *var* genes (Freitas-Júnior et al. 2000), the diversity of *var* genes in field isolates is very high \[e.g., data described in [@B49]\] turning the task of developing antibodies against most of the variants into a long-lasting process. Importantly, most of the circulating variants show cytoadherence to CD36 and the presence of this phenotype was associated with non-severe malaria episodes ([@B32]). Despite the great diversity of *var* genes and PfEMP1 variants, a number of alleles are fairly conserved between different isolates. An example of this are the *var* genes, which encode PfEMP1 versions expressed in pregnancy-associated malaria (PAM) (*var2csa*) ([@B24], [@B38]); the recognition of these variants is associated with the decrease of PAM symptoms ([@B45]). Another conserved group of *var* domains was recently revealed by the comparison of seven *P. falciparum* genomes ([@B37]). Three independent groups showed that up-regulation of the *var* genes expressing domain cassettes 8 (DC8) or DC 13 domains occurred in cases of severe childhood malaria ([@B7], [@B14], [@B25]). The receptor for these domains appears to be the endothelial protein C receptor (EPCR) ([@B44]). Another conserved phenotype of PfEMP1 encoded by DC4 domains ([@B33], [@B9]) seems to be associated with ICAM1-binding, which itself was correlated with severe (cerebral) malaria ([@B43]). Very little is known about the adhesion binding properties and antigenic variation related to the *var* genes and PfEMP-1 proteins in Amazonian isolates. Previous reports by our group based on the analysis of PfEMP1-DBLα encoding tags showed that the *var* gene repertoires seem much smaller in Amazonian *P. falciparum* isolates compared to other endemic settings ([@B2], [@B1]). It is also known that the absolute number of malaria-infected people in the Amazon may be underestimated due to a high incidence of asymptomatic infections in riverside settlements ([@B4]). Additionally, the occurrence of severe malaria is a rare event and seems to happen due to a late diagnosis outside the transmission area; consequently it is as lethal as in African settings. In absolute numbers, the mortality rate of *P. falciparum* malaria in Brazil is much lower than in Africa. Given a total of 265,000 cases and 76 deaths from malaria in Brazil in 2011 the mortality rate of malaria in Brazil was 0.029% compared to <0>.3% worldwide in the same year \[655,000 deaths out of 216 million cases worldwide in 2011 ([@B51])\]. Based on this information, we set out to explore whether the recognition of possibly less circulating antigenic variants (due to redundant circulating *var* gene repertoires) by antibodies in patient sera were correlated to asymptomatic outcomes of malaria and whether the phenotype associated with severe malaria - a parasite line most likely expressing a DC8 domain encoding *var* gene - was recognised even in the virtual absence of severe malaria. For this, we phenotype-selected four Amazonian *P. falciparum* isolates plus the non-related 3D7 strain based on the receptors CD36 and ICAM1 expressed on CHO cells. We then quantified IRBC recognition by plasma antibodies using flow cytometry.

SUBJECTS, MATERIALS AND METHODS
===============================

*Human plasma samples from symptomatic and asymptomatic individuals* - Human plasma samples were obtained during an epidemiological survey from persons living in the surroundings of Porto Velho, the capital of the state of Rondônia (RO) (Brazil). Ethical clearance was obtained from the Ethical Board of the Institute for Biomedical Sciences at São Paulo University and the Institute of Research on Tropical Pathologies before the start of the trial (protocol 741/2006). Each individual expressed his/her written consent to participate in the study. Participants were considered symptomatic when they presented with at least one clinical symptom (fever \> 37.8ºC, prostration, headache, chills, tremors, myalgia, nausea and/or vomiting) and positive parasitaemia was tested by a thick blood smear and/or polymerase chain reaction (PCR). Individuals who did not present with any clinical symptoms for up to 30 days after the blood withdrawal, but had tested positive for *P. falciparum* by PCR, were considered to be asymptomatic. All patients were treated with the adequate drugs (Coartem) directly after the molecular diagnosis. In total, 89 plasma samples from symptomatic individuals and asymptomatic individuals (the latter were residents of Santo Antônio, Bate-Estaca and Vila Candelária, communities next to the Madeira River) were tested.

*Parasites and static cytoadherence assay* -*P. falciparum* field isolates S20, 99, 106 and 134 were collected in RO ([@B2]). While the S20 strain was originally collected and culture-adapted by [@B40], the 99, 106 and 134 isolates were collected and culture-adapted during an effort to map the genetic diversity of *P. falciparum* in the western Amazon Region, but without the aim of monitoring cytoadherent phenotypes of the initial patient isolate \[Research Project São Paulo State Research Foundation (01/09401-0)\]. In consequence, the initial phenotypes were lost and not available for this work. The 3D7 strain was initially received by [@B48]. All parasites were cultured in candle jars as described ([@B42]) using RPMI-1640 medium supplemented with 10% human plasma (type A or AB) and O^-^ erythrocytes. The parasites were selected for the expression of the determined PfEMP1 variants using static cytoadherence assays as described by [@B17]. Briefly, 10^8^ trophozoite infected RBCs were incubated over CHO-ICAM or CHO-CD36 cells (a generous gift from Dr Artur Scherf, Pasteur Institute, Paris) and were cultured to confluence in 25 cm^2^ culture bottles. Unbound parasites were then removed by three subsequent washings with RPMI at pH 6.8 and the still-bound parasites were detached by incubation with RPMI at pH 7.4 and cultivated with fresh RBCs. This procedure was repeated five times, after which a homogenous binding phenotype was achieved. To measure the achieved cytoadherence properties, 5 x 10^5^ CHO cells expressing either CD36 or ICAM1 were seeded in labtec slides and were grown for 48 h. Mature trophozoite/early schizont stage parasites were prepared from mixed cultures by plasmagel flotation ([@B27]). Cytoadherence was then measured by the incubation of 5 x 10^6^ trophozoite stage parasites over the cells for 1 h. After this, the supernatants were aspirated and the cells were washed three times with incomplete RPMI medium at pH 6.8. Next, the slides were stained and five fields were counted under a 1:1,000 magnification. The parasite lines were judged clonal after testing 11 microsatellites ([@B5]) during previous research (L Albrecht, unpublished observations). The 3D7 lines, which dominantly transcribed *var* PF11_0521 and PFD0020c, were identified after clonal selection using limiting dilution on previously CHO-CD36 and CHO-ICAM panned parasites, respectively.

*Reverse transcription (RT)-PCR and sequencing analysis*- For determining the dominant *var* transcript in field isolates and 3D7 parasites, the RNAs of 10^8^ ring stage parasites were recovered from each parasite line using the Trizol^®^ method (Invitrogen). All of the RNAs were submitted to RT using random hexamer primers and RevertAid Reverse Transcriptase (Fermentas) following the manufacturer's instructions. Then, the DBLα tag sequences were amplified using the oligonucleotides also employed by [@B49]. The resulting \~400 bp fragments were recovered from TAE-agarose gels and cloned into pGEM T-easy (Promega) vectors and 50 clones per lineage were sequenced in an ABI 3100 (Applied Biosystems) automated DNA sequencer. The sequences were analysed using CLUSTALX 1.83 and similarity to known DBLα tags was searched using the National Center for Biotechnology Information's and PlasmoDBs BLAST ([@B3]) website. The resulting DBLα tag sequences were then analysed for their distinct sequence identifiers (DSID) using the Perl script published by [@B11]. The DSID classification is based on the analysis of four semi-conserved tetrapeptides (positions of limited variability) and the number of cysteines found in the DBLα region flanked by the oligonucleotides used herein, resulting in six groups of DSIDs. By comparison with the previously established classification of the 5' untranslated regions (UTR) of the *var* genes \[upstream sequences (ups) ([@B24])\], DBLα sequences of DSID groups 1-3 were mostly associated with upsA type 5'-UTR sequences, while DSID groups 4-6 were associated with upsB and upsC 5'-UTR sequences ([@B11]).

*Immunofluorescence*- Live parasite immunofluorescence assays were conducted with enriched *P. falciparum* trophozoites and human plasmas from asymptomatic and symptomatic carriers. For this, trophozoite/schizont stage parasites were incubated with 40 µg/mL of 4'-6-diamidino-2-phenylindole and HCS CellMask in 100 µL RPMI/1% bovine serum albumin for 60 min at 37ºC, followed by incubation with plasma (dilution 1:25) and an Alexa Fluor labelled antihuman-IgG antibody (Molecular Probes, 1:200 dilution). Between each incubation step, the material was washed three times with RPMI pH 7.2 and was visualised in fluorescence microscopy. As a control, we employed the antiglycophorin antibody (1:1,000 dilution) (Molecular Probes) and a secondary antibody, anti-mouse-IgG 1:500 (Alexa Fluor 594, Molecular Probes).

*Flow cytometry* - For the flow cytometry assays, the trophozoites were resuspended in RPMI pH 7.2 and 2% of bovine foetal serum (RPMI-S). Briefly, 5 x 10^6^ parasites in blood at a parasitaemia of \< 0.5% were incubated for 30 min with donor plasma, including as a control a plasma pool from persons who were never infected with malaria (1:10 dilution) in RPMI-S. This was immediately followed by antigoat IgG conjugated with Alexa Fluor 488 (1:200 dilution) for 30 min. After that, the parasites were incubated with ethidium bromide \[100 µg/mL in phosphate buffered saline (PBS) 1X\] for 20 min to perform the nuclear labelling of the parasitised erythrocytes. After washing, the RBC solutions were resuspended in PBS to an average concentration of 500 cells per µL and were analysed in a Guava EasyCyte Mini flow cytometer. For each plasma sample, 5,000 events were monitored and analysed using the Guava EasySoft software. The surface labelling of the IRBCs was expressed as a reactivity index (RI). For this, we established a cut-off value that measured baseline surface labelling using the non-reactive pool of plasma samples against each parasite lineage. Then, the average immunofluorescence values of each plasma sample measured in duplicate were divided by the average signal plus three standard deviations obtained from the negative plasma pool. All plasma samples with RI above 1 were considered reactive.

*St* *atistical analyses* - All of the statistical analyses were performed using Prism GraphPad5 software. For the comparison of the ratio of responders/non-responders against phenotype-expressing parasite lines, Fisher's exact test was applied. For the comparison of the RI values between different groups of plasma samples and/or parasite lines, Mann-Whitney's *U* test was applied.

RESULTS
=======

*Cytoadherent-selected isolates show in part identical var DBLα sequences, but no selection of determined var type subclasses* - In order to identify an association between *var* gene transcription and cytoadherent phenotypes in the Amazonian field isolates tested in this study, we used RT-PCR followed by cloning/sequencing of the amplified products. This is currently the only applicable non-high throughput method for *var* gene analysis with unknown genome sequences. Fifty clones were sequenced per isolate and adhesive phenotype (CHO-CD36 or CHO-ICAM), resulting in six-16 different sequences per isolate. All isolates showed one dominant DBLα sequence ([Fig. 1](#f01){ref-type="fig"}). Severe malaria cases were recently related to the expression of upsA-related DBLα sequences ([@B49]) and these fall into DSID groups 1-3 \[defined by Bull et al. (2005, 2007)\]. Accordingly, we classified the sequences according to their DSID group using the criteria developed by [@B11] described above. The abundance of sequences with specific DSID types varied between parasite lines. For example, the dominant sequence (46%) in the 3D7~PFD0020c~ line was DSID type 1, while 38% were of DSID types 4-6 in this parasite line. However, panning of the parasites on CHO-ICAM, which should ideally result in DBLα DSID type 3 (PF11_0521) expressing parasites, failed to result in such parasites and all parasites panned over this receptor showed only low frequencies of DBLα DSID 1-3 expressing parasites that were previously associated with severe malaria ([@B10]) ([Fig. 1](#f01){ref-type="fig"}). Alignment of all the sequences also showed that highly similar *var* DBLα sequences (\> 95% sequence identity) were identified in 106~ICAM~, S20~ICAM~ and 99~ICAM~, indicating that at least the DBLα domains in the expressed PfEMP1 proteins seem similar, reinforcing the somehow redundant *var* repertoires in these parasites. Unexpectedly, the selection over CHO-CD36 in two cases led to the expression of dominant DSID type 1-3 sequences in parasite lines S20 and 99. The selection of the 3D7 strain for CHO-ICAM adherence showed that the dominantly present *var* gene transcripts PFL1970w and PFD1000c were not exactly the ones identified previously by our group ([@B17]), nor were they PF11_0521, which contains the unique DBLβ/C2 domain that strongly interacts with ICAM1 in vitro ([@B33]) or PFD1235w, as identified by [@B9]. In fact, PFL1970w and PFD1000c do not even contain a DBLβ/C2 sequence at all ([@B37]), making their participation in ICAM1-binding doubtful. Selection of the 3D7 line on CHO-CD36 led to the expression of PFD0615c as previously published ([@B17]). We also tested two 3D7 lines that were previously encountered in cloning experiments and either expressed the *var* gene PFD0020c (3D7~PFD0020c~), which is associated with severe malaria ([@B25]) or PF11_0521 (3D7~PF11_0521~), which contains the ICAM1 binding domain ([@B33]). In a second approach, we tried to identify whether any of the identified DBLα sequences were similar to DBLα domains that were connected to the severe *var*-associated domains DC8 and DC13 and the ICAM1 binding phenotype DC4 in the seven *P. falciparum* genomes that were analysed by [@B37]. For this, we aligned the DBLα DNA sequences with sequences retrieved from their dataset. The sequence expressed in the CHO-CD36 selected S20 line (S20~CD36~) expressed a DBLα tag similar to IT4var35, a sequence that is closely related to *var1csa*, while the dominant sequence in the CHO-CD36 selected line 99 was identical to PFD1000c, which is an upsC1 type *var* gene ([@B37]). Because all of the remaining sequences from the 99 isolate were not similar to the 3D7 counterparts, we concluded that no cross-contamination had occurred during the selection process, which was also true for all other tested isolates ([Fig. 1](#f01){ref-type="fig"}). No other DBLα sequences showed significant similarity to DBLα domains, which were connected to DC8, DC13 or DC4 domains from the published dataset from seven genomes ([@B37]), suggesting that they are most likely not part of the *var* genes encoding PfEMP1 containing this type of domain. We concluded that the produced phenotypes, despite their apparent adherence to given CHO lines expressing ICAM1 or CD36, do not necessarily express PfEMP1, which can be related to any specific disease-associated phenotype. At a minimum, the selection of 3D7 must have resulted in at least the marginal expression of either the PFD1235w or PF11_0521 *var* genes, which was not the case ([Fig. 1](#app02){ref-type="app"}, Supplementary data [Fig. 4](#app05){ref-type="app"}). Therefore, it can only be assumed that the selected parasite phenotypes express distinct PfEMP1s, with the exception of the lines 106~ICAM~, S20~ICAM~ and 99~ICAM~.

Fig. 1: frequency of clones with *var* transcripts from different parasite lineages suggests the expression of few dominantly expressed *var* genes in each lineage. Shown are the frequencies of occurrence of determined *var* DBLα sequences which were obtained by reverse transcription-polymerase chain reaction fragment cloning and sequencing of 50 clones per lineage. A: the frequency of sequence types in 3D7 parasite clones 3D7PFD0020c and 3D7Pf11_0521; B: the frequencies of sequence types detected in 3D7 parasites panned over CHO-CD36 or CHO-ICAM1; C-F: the results from panned parasite isolates S20, 99, 106 and 134. The most frequently found transcript sequences per isolate are indicated together with their distinct sequence identifiers classification (bold) and the identity of the most similar DBLα tag DNA sequence from the 3D7 genome are shown in parenthesis. The most similar 3D7 DBLα tags were S20ICAM (PFL1950w), S20CD36 (PFI1820w), 99ICAM (PFL1950w), 99CD36 (PFD1000c), 106ICAM (PFL1950w), 106CD36 (Mal6P1.316), 134ICAM (PFD0630c) and 134CD36 (PFD0995c). The x-axis numbers in each graph depict the sequences and the corresponding accessions can be retrieved in Supplementary data [Fig. 4](#app05){ref-type="app"}.

*F* *low cytometry analysis revealed a consistent presence of antibodies against the 3D7* ~*PFD0020c*~ *and 3D7* ~*Pf11_0521*~ *phenotypes* - We tested the IRBC surface recognition of antibodies contained in plasma samples from 44 symptomatic and 45 asymptomatic individuals. Immunofluorescence assays revealed that IRBCs were recognised in a specific way and showed labelling only on the surface of IRBC, but not on normal RBCs. Additionally, no staining of parasites inside the IRBCs was observed (Supplementary data [Fig. 1](#app02){ref-type="app"}). We then measured the recognition of field isolates/phenotypes by antibodies contained in the plasma of symptomatic and asymptomatic individuals by flow cytometry and calculated the RI for each plasma and parasite line tested. When we compared the percentage of positive plasma samples for parasite lines (RI higher than 1), we observed that the 3D7 isolates selected for CHO-ICAM1 and CHO-CD36 were recognised by more plasma samples from asymptomatic individuals than those from symptomatic individuals ([Fig. 2](#f02){ref-type="fig"}) (Fisher's exact test, p = 0.0184 and p = 0.0079, respectively). However, recognition of the 3D7~Pf11_0521~ phenotype was more frequent in symptomatic individuals (p = 0.0148). No significant differences in the number of plasma samples recognising all other parasite lines were detected (p \> 0.05) when comparing the recognition by plasma samples from symptomatic and asymptomatic individuals. When comparing the recognition of the different 3D7 phenotypes by plasma samples from asymptomatic individuals, the 3D7~Pf11_0521~, 3D7~ICAM~ and 3D7~CD36~ phenotypes were less frequently recognised than 3D7~PFD0020c~ (p \< 0.0001). Most of the phenotypes, excluding the phenotype-selected 3D7 parasites, were recognised by 40-80% of the plasma samples ([Fig. 2](#f02){ref-type="fig"}). The 3D7~PFD0020c~ lineage was recognised by the most plasma samples and it also had the highest RI ([Fig. 2](#f02){ref-type="fig"}, [Table I](#t01){ref-type="table"}). In order to estimate the previous exposure of all of the individuals to malaria attacks, we measured antibodies against a recombinant version of the highly conserved C-terminus from merozoite protein 1 as a surrogate marker, given that the number of informed, previous malaria attacks was not predictive for a stronger or weaker recognition (Supplementary data, [Table](#app01){ref-type="app"}). As shown in Supplementary data ([Table](#app01){ref-type="app"}), the majority of individuals presented detectable to high titres of antibodies against PfMSP1~19~. On the other hand, low titres were not paralleled by a weak or absent reaction against the RBC surface, suggesting diversity in the response to malarial antigens. The same was true when comparing the number of informed infections with either titre level in the MSP1~19~ ELISAs or IRBC recognition. We then individually analysed whether any of the phenotypes were recognised more strongly by plasma samples from either asymptomatic or symptomatic individuals. Significant differences and a stronger recognition (higher RI values) by plasma samples from asymptomatic individuals were indeed observed for the parasite lines S20~CD36~, 3D7~PFD0020c~, 3D7~ICAM~ and 3D7~CD36~, while 134~CD36~ and 3D7~Pf11_0521~had higher RI with plasma samples from symptomatic individuals. The remaining phenotypes were not differentially recognised by symptomatic or asymptomatic donor plasma samples ([Table II](#t02){ref-type="table"}, Supplementary data [Fig. 2](#app03){ref-type="app"}). Additionally, we asked whether plasma samples recognised specifically more of the CHO-ICAM or the CHO-CD36 selected phenotype of each isolate. We also compared the recognition intensities of the specific 3D7 phenotypes 3D7~PFD0020c~and 3D7~Pf11_0521~ with their panned counterparts 3D7~CD36~ and 3D7~ICAM~. Eventual differences here may inform about the relative participation of antiPfEMP1 antibodies in recognition when we assume that all other possibly exposed variant antigens, such as RIFINs, STEVORs and others, have either a smaller participation in recognition or are not differently expressed after the phenotype selection process. Interestingly, in all cases, the ICAM1 phenotype was more strongly recognised than the CD36 phenotype, independently of the origin of the plasma. In the majority of cases, the difference in recognition was significantly different ([Table I](#t01){ref-type="table"}, Supplementary data [Fig. 2](#app03){ref-type="app"}). As was true for the percentage of plasma samples that reacted against this phenotype, the recognition of 3D7~PFD0020c~ was significantly higher in all plasma samples compared to the recognition of any other 3D7 phenotype. The phenotype 3D7~Pf11_0521~was also very strongly recognised. Both phenotypes were significantly more likely to be recognised than the other 3D7 phenotypes 3D7~CD36~and 3D7~IC~ ~AM~ ([Table I](#t01){ref-type="table"}, Supplementary data [Fig. 2](#app03){ref-type="app"}), although plasma samples from asymptomatic carriers did not react differently against the 3D7~Pf11_0521~phenotype compared to the 3D7~ICAM~ or 3D7~CD36~ phenotypes.

Fig. 2: most plasma recognises the 3D7PFD0020c phenotype. The percentage of responders of each plasma donor group was plotted against the recognised parasite lineage. Asterisks mean significant differences between the percentages of recognising plasmas from the asymptomatic and symptomatic group (Fisher's exact test).

TABLE IMany plasma recognise more the CHO-ICAM selected lineage of parasites than the CHO-CD36 selected lineage p (plasmas symptomatic individuals)p (plasmas asymptomatic individuals)S20~ICAM~↑ vs. S20~CD36~0.00850.970699~ICAM~↑ vs. 99~CD36~0.03190.0137106~ICAM~ vs. 106~CD36~0.06230.9005134~ICAM~↑ vs. 134~CD36~0.03590.81163D7~PFD0020c~ vs. 3D7~Pf11_0521~↑0.3682\< 0.00013D7~ICAM~↑ vs. 3D7~CD36~0.04460.03663D7~PFD0020c~↑ vs. 3D7~ICAM~\< 0.0001\< 0.00013D7~PFD0020c~↑ vs. 3D7~CD36~\< 0.0001\< 0.00013D7~Pf11_0521~↑ vs. 3D7~ICAM~\< 0.00010.35083D7~Pf11_0521~↑ vs. 3D7~CD36~\< 0.00010.2850[^1]

TABLE IIComparison of reactivity indices (RI) from plasmas originating from asymptomatic and symptomatic individuals shows differing patterns of recognitionTested parasite lineageS20~ICAM~S20~CD36~99~ICAM~99~CD36~106~ICAM~106~CD36~3D7~PFD0020c~3D7~Pf11_0521~134~ICAM~134~CD36~3D7~ICAM~3D7~CD36~p0.84170.04580.83100.84320.23310.57360.01000.02520.07070.01130.00230.0098[^2]

The huge range of reactivity observed against the different 3D7 phenotypes expressing different alleles of PfEMP1, seen as the presence of dominant transcripts of the different *var* genes in the corresponding parasites, appears to highlight the importance of PfEMP1 recognition in the overall response against IRBC.

DISCUSSION
==========

Antibodies directed to the surface of *P. falciparum*-IRBC are important players in combating the symptoms and virulence of malaria and the recognition of PfEMP1 seems to be of major importance ([@B12], [@B13]). Many studies from epidemic sites in Africa and Southeast Asia have shown that the cumulative acquisition of antibodies against a great number of antigenic phenotypes provides protection from malaria. The degree of acquired immunity ranges from protection initially from death, then from severe outcomes and finally from symptomatic malaria ([@B20], [@B29]). As a consequence, it is believed that continuously exposed individuals do not necessarily suffer from malaria, but become asymptomatic carriers. Additionally, it is hypothesised that during the first infections (at least in childhood malaria in Africa), a few conserved PfEMP1 phenotypes are expressed and lead to an increased severity of disease, which potentially occurs via the mechanism postulated by [@B44]. The authors proposed that by blocking the interaction of soluble protein C through the binding of a DC8/DC13 PfEMP1 domain, endothelial activation is induced, which then leads to the up-regulation of inflammatory signals, including the increased expression of endothelial ICAM1 and other receptors. As a consequence, the DC8/DC13 containing PfEMP1 phenotypes would be the first to be recognised by persons who did suffer severe malaria episodes. *P. falciparum* infection in the Brazilian Amazon is currently decreasing and transmission is unstable in many places. Symptomatic cases seem to accumulate in areas with a strong influx of non-immune populations, such as rural settlements, wood logging or mining activities ([@B34]). Perhaps as a consequence of low transmission and quick treatment, the overall diversity of variant protein encoding genes, such as the *var* genes, in the Amazon seems much smaller than in any other endemic area so far tested ([@B2]); development to severe malaria is also likely prevented by quick treatment. The herein used isolates possess *var* genes, which represent part of the repertoire of circulating strains in the Amazon ([@B1]). In order to elucidate the differential presence of antibodies against the IRBC surface in asymptomatic ("protected") and symptomatic ("susceptible") individuals, we tested the recognition of *P. falciparum* isolates from the western Brazilian Amazon and compared them to four lineages of 3D7 that expressed different *var* genes/PfEMP1. These included the virulence-associated phenotypes, which expressed either the *var* gene PFD0020c ([@B25], [@B44]) or Pf11_0521, one of the ICAM1-binding PfEMP1 variants of the 3D7 genome ([@B33]).

For the preparation of relevant phenotypes in natural isolates, we tried to focus on two main cytoadherent phenotypes that are supposedly expressed either in non-severe malaria (CD36 adherence) or severe malaria (ICAM1 adherence) ([@B32]), although the latter possibly occurs in consequence to previous EPCR-adherence ([@B44]). We tried to prepare these phenotypes by panning the isolates over receptor-transfected CHO cells ([@B19]). Although our group had previously shown the usefulness of this quite economic cytoadherence selection approach using the 3D7 strain ([@B17]), this method cannot warrant that the selected parasites indeed use the most affine PfEMP1 for a defined receptor. One example is the 3D7 line selected on CHO-ICAM cells. Although the parasite line also showed the PFD1000c transcript, the dominant transcript was now PFL1970w ([Fig. 1](#f01){ref-type="fig"}) and not PFF0845c, as described previously by us ([@B17]). On the other hand, PfEMP1, which contains the most domains that bind strongly to ICAM1, is present in PF11_0521 ([@B33]), although the upsA type PFD1235w also contains ICAM1 binding domains ([@B9]). This means that other receptors - and not ICAM1 - seem to be recognised. Several issues must be taken into account when using the assay employed in this study: first, there are additional receptors on CHO cells, which can be recognised by PfEMP1 domains ([@B6]). Potentially the binding affinity to ICAM1 on the CHO-ICAM cells is not superior to the other unknown receptors present on the CHO cells, leading to varying dominant transcripts in different experiments that use the CHO-ICAM cells. Given the *var* transcript sequence results from each parasite line panned over CHO-ICAM, we deduced that the method was not suitable for the directed selection of truly ICAM binding IRBCs. Second, the expression of the desired receptor molecules varied on the CHO-cell lines and frequent checks are necessary to assure that the receptors are indeed still expressed. During our experiments, we checked whether the cells sufficiently expressed the respective receptor using specific antibodies against human CD36 and ICAM1 in immunofluorescence assays (data not shown). We also checked whether some isolates showed the most cytoadhesion to the CHO-cell line they were selected for. As depicted in Supplementary data [Fig. 3](#app04){ref-type="app"}, all isolates did adhere more to the cell line they were selected for, but they also showed cytoadherence to other CHO lines. The observation of simultaneous CD36 and ICAM1-binding phenotypes has been documented before \[for example, [@B39]\]. In favour of the system used in this study, cytoadherence to receptors was partially inhibited by co-incubation with specific antibodies to CD36 and ICAM1 (data not shown). One alternative to cellular systems for cytoadherence selection would be the use of purified receptors, which has been done successfully by other groups, at least for CSA or ICAM1-binding parasite lines \[see protocols published by J Reeder in [@B31]\]. We tried using commercially available purified human ICAM1 spotted on plastic dishes, but the yields per selection round were too poor and this approach was abandoned (BC Carlos, unpublished observations). An additional concern regarding this method is the fact that naturally occurring receptors are embedded in or associated to membrane bilayers and are surrounded by vast arrays of glycosyl rests that are present on each cell surface. This is not the case when purified and recombinant receptors are used, which may consequently influence the cytoadherence strength.

After the panning selection using the field isolates, we observed dominant *var* transcripts in all parasite lines, indicating that we were potentially analysing phenotypically homogenous cultures. The DBLα-specific oligonucleotides used for the *var* transcript amplification were previously used in a number of studies by us and others \[e.g., [@B49]\] and permitted estimation of the corresponding sequences were associated to specific ups (upsA, B and C) using the DSID analysis approach ([@B11]). Importantly, the *var* genes preceded by the upsA type sequences were found to be expressed in cases of severe malaria ([@B10], [@B49]), while the upsB and upsC sequences were not. The classification was greatly refined with the analysis of the variant genes from seven *P. falciparum* genomes ([@B37]) and a novel quantitative PCR based approach now permits a rather detailed classification of *var* transcripts ([@B25]). When trying to classify the obtained field isolate transcripts, we observed that most of these fell into upsB and upsC types of transcripts (DSID types 4-6) and unexpectedly, only the dominant sequences from S20~CD36~ and 106~CD36~ presented the upsA type sequence. The identified sequence of S20~CD36~, however, was quite similar to the *var1csa* sequence \[most similar to ITvar35, upon alignment to the dataset that was published in [@B37]\], which is a transcript consistently transcribed by many parasites, but apparently not encoding a functional PfEMP1 protein ([@B22]). It is difficult to interpret why CHO-CD36 panning induced a parasite line to express an upsA sequence type. Considering the procedure by which the isolates and the panned 3D7 strains were phenotypically selected for and given that the detected *var* gene transcripts, with two exceptions, did not fall in the DSID groups that were associated with severe malaria cases, we suggest that the phenotypes we looked at will most likely not be found in severe cases in a field situation, but in non-severe cases. When we monitored the antibody recognition of the different parasite lines, we observed a strong recognition of severe malaria-associated phenotypes, such as the 3D7~PFD0020c~ and 3D7~Pf11_0521~ parasite lines. This indicates that the severe malaria associated DC8/DC13 phenotype is present and circulating in Amazonian isolates. This strong recognition occurred in a similar form with plasmas from symptomatic and asymptomatic individuals, although we did not detect antibodies in all samples. Following the hypothesis that the first malaria infections lead to more severe disease in non-immune carriers, which is characterised by the expression of *var* genes from the DC8 and DC13 groups, including PFD0020c ([@B7], [@B14], [@B25]) and perhaps the DC4 group *var* genes ([@B9]), one would expect that at least asymptomatic plasmas would contain specific antibodies for this phenotype. Potentially not all Amazonian *P. falciparum* isolates contain severe malaria associated *var* genes or there may be antigenically very different, not yet described variants that we did not test in this study. The existence of a selection system that permits purifying and enriching EPCR-binding phenotypes would be very useful to discover Amazonian severe *var* variants. However, it is possible that the severe *var* phenotype is only induced after a certain duration of infection and quick treatment (less than 48 h after onset) as is common in the Amazon would prevent the quantitative outgrowth of this phenotype. In consequence, these individuals would not necessarily react to the severe *var* phenotype. In one study, the controlled natural infection of non-immune individuals with the 3D7 strain led to the expression of severe *var* PFD0020c or PFD1235w in only two out of six volunteers only on days 3-4 after the onset of infection ([@B23]).

Based on the analysis of the DBLα motifs, we have previously found that almost no sequences are shared between Amazonian isolates and the 3D7 strain ([@B1]). This finding may explain why the panned 3D7 lines that adhere to CD36 and ICAM1 and express non-PoLV1-3 (non upsA) type *var* genes were only weakly recognised by the plasma samples and significantly less by the plasma samples from symptomatic patients. The recognition of the field isolates occurred in approximately 40-70% of each lineage by the plasma samples from each group, while the panned 3D7 variants were recognised much less frequently. As expected, the recognition of phenotypes was often stronger by the asymptomatic plasma samples. In previous studies, the reaction of antibodies against the IRBC surface was estimated using parasite lines that specifically expressed no PfEMP1 (PfEMP1 knockdown) or had impaired transport of PfEMP1 and other IRBC surface localised proteins (SBP-1 knockout). The knockdown of PfEMP1 only decreased the IRBC surface recognition by antibodies from a serum pool of malaria-experienced persons by approximately 70% compared to the normal PfEMP1-displaying IRBCs ([@B47]). In the absence of other proteins besides PfEMP1 in the SBP-1 knockouts, there was a 90% decrease in IRBC surface recognition by immune sera ([@B28]). This indicates that a major portion of the antibodies against the IRBC surface is directed against the PfEMP1 proteins.

One of the goals of this study was to reveal whether the occurrence of asymptomatic malaria was paralleled by a significantly stronger presence of anti-IRBCs. While this was the case in recognition frequency and the antibody RI against many of the parasite lineages tested in this study, there were still a number of plasma samples in the asymptomatic group that reacted poorly against many phenotypes. This indicates that protection in these specific individuals is potentially quite fragile and is directed against a very limited repertoire of variant antigens, most of which were not present in this study. Another explanation is that the recognition of the IRBC surface is not crucial for the establishment of an asymptomatic status, at least not under the transmission conditions where the plasma donors lived. We did not test the IgG subclasses that reacted to the surface of the parasites and this may also be an important factor for achieving humoral immunity against the IRBC surface. A recent study using plasma samples from the same site tested the recognition of merozoite surface antigens in asymptomatic and symptomatic populations ([@B30]) and the authors observed similar patterns of recognition: while many of the asymptomatic patients recognised most of the antigens tested, a number of individuals did not recognise those antigens. Therefore, we propose that the recognition of many interchangeable targets may provide protection from symptoms under the transmission conditions of the western Amazon. The recent detection of EPCR as relevant receptor for cytoadherent IRBC ([@B44]) and the establishment of a system to quickly select for parasite phenotypes that express the severe *var* related PfEMP1 should provide a useful tool to focus attention on the question of whether *P. falciparum* with decreased virulence exist, which could potentially provide a biological explanation for the virtual absence of severe malaria in the Brazilian Amazon.
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[^1]: the significance of differences in reactivity indices of plasmas either from asymptomatic or symptomatic individuals reacting either against the CHO-ICAM or the CHO-CD36-selected parasite lineage was evaluated by Mann-Whitney's *U* test without normalisation of the data. Shown are the resulting p values. The arrows indicate which lineage was statistically more recognised.

[^2]: the significance of difference of the RI from asymptomatic and symptomatic patient's plasmas reacting against the shown parasite lineages was evaluated using Mann-Whitney's *U* test without normalisation of the data. Note that 134~CD36~ and 3D7~Pf11_0521~ were recognised stronger by plasmas from symptomatic infections.
